Evidence map›Paper›PMID 22306336›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2012

Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera.

Poonam Chopra, Jinsong Hao, S Kevin Li

Abstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Controlled ocular drug delivery with nanomicelles.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Poonam ChopraDivision of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. choprap@mail.uc.edu
Jinsong Hao
S Kevin Li
University of Cincinnati Medical Center · USUniversity of Cincinnati · US

Funding

TISSUE DISTRIBUTION FOR RARE DISEASE RESEARCHU42RR006042 · NCRR · NATIONAL DISEASE RESEARCH INTERCHANGE · PI LONSDALE, JOHN T · 1991 to 2011
$16.5M
Methods &Noninvasive PK Study to Improve IontophoresisR01EY015181 · NEI · UNIVERSITY OF UTAH · PI LI, KEVIN S. · 2005 to 2010
$1.3M
NCRR NIH HHS 5 U42 RR006042NCRR NIH HHS U42 RR006042NEI NIH HHS EY 015181NEI NIH HHS R01 EY015181
6 · The paper itself

Abstract

A challenge in ocular drug delivery is to maintain the therapeutic concentration of a drug at the site of action in the eye. The objective of the present study was to investigate the feasibility of micellar carrier systems for sustained drug delivery in transscleral iontophoresis in vitro. Simple and mixed micelles prepared using sodium taurocholate (TA) alone or with egg lecithin (LE) were the carrier systems studied. Dexamethasone (DEX), a poorly water soluble corticosteroid, was the model drug. The micellar carrier systems were first characterized for their solubilization and encapsulation of the drug. Passive and 2-mA iontophoretic (both cathodal and anodal) transport experiments were conducted using these micellar carrier systems in side-by-side diffusion cells with excised human sclera in vitro. Drug release studies were performed after the transport experiments. Saturated DEX solution without the micellar carriers was used as a control. It was found that the solubilization capacity of the micellar carrier systems increased as the total lipid concentration of the systems increased. Drug release from the sclera was significantly prolonged with the micellar carrier systems as compared to the control after passive and iontophoretic delivery. Less than ~20% of DEX was released from the sclera in approximately 2h after cathodal iontophoretic delivery of the micellar carrier systems, whereas more than ~50% of DEX was released from the control in the same time period under the same condition. Micellar carrier systems can be a suitable transscleral drug delivery system for poorly water soluble drugs by enhancing their aqueous solubilities and providing sustained drug delivery. These micellar carrier systems can be efficiently delivered into and across the sclera by iontophoresis for drug delivery.

Indexed as

CadaverCell Membrane PermeabilityDelayed-Action PreparationsDexamethasoneDrug CarriersDrug CompoundingFeasibility StudiesGlucocorticoidsHumansIn Vitro TechniquesIontophoresisMicellesModels, BiologicalParticle SizeScleraSolubilityDelayed-Action PreparationsDexamethasoneDrug CarriersGlucocorticoidsMicelles

Identifiers

PMID22306336
PMCPMC3372542
OpenAlexW2022110842

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.